Half-year report · Q2
3353.TEDINET S100UIUM
Period2024-03-01 → 2024-08-31
Filed2024-10-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥22.7bn | 2024-03-01 → 2024-08-31 | Cons. | Net sales |
| Revenue | ¥39.9bn | 2023-03-01 → 2024-02-29 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.5bn | 2023-03-01 → 2023-08-31 | Cons. | Net sales |
| Operating income | ¥828m | 2024-03-01 → 2024-08-31 | Cons. | Operating income |
| Operating income | ¥603m | 2023-03-01 → 2023-08-31 | Cons. | Operating income |
| Ordinary income | ¥853m | 2024-03-01 → 2024-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-03-01 → 2024-02-29 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥697m | 2023-03-01 → 2023-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2024-03-01 → 2024-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥776m | 2023-03-01 → 2023-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥710m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2023-03-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥444m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥728m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss |
| Net income | ¥469m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss |
| Total assets | ¥33.1bn | at 2024-08-31 | Cons. | Assets |
| Total assets | ¥31.7bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥28.5bn | at 2023-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥18.7bn | at 2024-08-31 | Cons. | Liabilities |
| Total liabilities | ¥17.8bn | at 2024-02-29 | Cons. | Liabilities |
| Net assets / equity | ¥14.4bn | at 2024-08-31 | Cons. | Net assets |
| Net assets / equity | ¥13.8bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥13.1bn | at 2023-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.2bn | at 2024-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.7bn | at 2024-02-29 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.1bn | at 2024-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2024-02-29 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.5bn | at 2023-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2023-02-28d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.3bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥848m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥675m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.2bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥338m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥354m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥278m | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥217m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥188.75 | 2024-03-01 → 2024-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥276.7 | 2023-03-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.26 | 2023-03-01 → 2023-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 41.6% | at 2024-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.8% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.9% | at 2023-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2024-08-31 | −¥110m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥551m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥128m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥7.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥6.7bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥399m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥194m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥65m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-03-01 → 2024-08-31 | ¥23.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-03-01 → 2024-08-31 | ¥22.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥401m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-03-01 → 2024-08-31 | ¥938m |
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-08-31 | −¥296m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥688m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥111m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥2.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥1.6bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥470m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥34m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥66m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-08-31 | ¥17.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥472m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-08-31 | ¥899m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | CurrentYTDDuration | 22665446000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 551175000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 127634000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 194184000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 65425000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 938420000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -110104000 | JPY |
| Operating income | CurrentYTDDuration | 828316000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)東海財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-10-11 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第40期中（自 2024年３月１日 至 2024年８月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社メディカル一光グループ | |
| Company name in english cover page | FilingDateInstant | Medical Ikkou Group Co.,Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 南野 利久 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)三重県津市西丸之内36番25号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)059－226－1193（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)常務取締役 経理部・関東支社担当 兼 財務・ＩＲ部長 遠山 邦彦 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)三重県津市西丸之内36番25号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)059－226－1193（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)常務取締役 経理部・関東支社担当 兼 財務・ＩＲ部長 遠山 邦彦 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E03443 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 33530 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社メディカル一光グループ | |
| Filer name in english | FilingDateInstant | Medical Ikkou Group Co.,Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-03-01 | |
| Current period end date | FilingDateInstant | 2024-08-31 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-02-28 | |
| Previous fiscal year start date | FilingDateInstant | 2023-03-01 | |
| Comparative period end date | FilingDateInstant | 2023-08-31 | |
| Previous fiscal year end date | FilingDateInstant | 2024-02-29 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |